IoN Trial
IoN is a multicentre phase II/III asking is ablative radioiodine necessary for low risk differentiated thyroid cancer patients. 560 patients will be recruited and randomised 1:1 to receive radioiodine ablation or no ablation. Samples collected during trial: Stimulated Tg blood samples for patients taken at the treatment visit, 2 months post treatment, 6-9 months post treatment and every 6 months thereafter for 5 years.
Existing samples:
- Malignant tumor of thyroid gland (disorder)
Contact Information
- Email:
- ctc.ion@ucl.ac.uk
- Address:
-
90 Tottenham Court road
London
Greater London
W1T 4TJ
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2025 | N/A | N/A | N/A | N/A | N/A | N/A |